by Raynovich Rod | Apr 10, 2023 | 2020-21 Life Science Portfolios, Biopharmaceuticals
4/19/23 1:30 P EDT…Update-3..Added to MedTech weighting in healthcare portfolios: ABT,HOLX, IHI. Talc liabilities weighing on JNJ shares, but sales growth up 5.6%, MedTech bright spot up 7.3%. Abbott (ABT) soars over 7% to $112 level on earnings with recovery...
by Rod Raynovich | Mar 31, 2023 | 2020-21 Life Science Portfolios, Macro
Biotech and Life Science Trades Q1 2023 By the Numbers Leading sectors in Q1 were Tech and Semis.The SPY was up 7% YTD. Small caps beginning to trend up. Healthcare lagging XLV down 5.5% as investors rotate into growth. Despite a strong month and a great finish to the...
by Raynovich Rod | Mar 27, 2023 | 2020-21 Life Science Portfolios, 2023 Rayno Biopharmaceuticals Portfolio
Update-1 3/28/23..Sector rotation continues with energy, materials leading today and healthcare, technology down slightly. Consumer confidence rises to 104.2 despite bank failures. Commodities strong.VikingTherapeutics (VKTX) rose 69% on Phase 1 data for Dua...
by Raynovich Rod | Mar 19, 2023 | 2020-21 Life Science Portfolios, Macro
Update-2 3/24..12;15p ..Biopharma and healthcare stocks rally. Update over weekend. ABBV AMGN BIIB GILD REGN VRTX and UNH and Medtech ISRG MDT…small caps EVH PACB. Update-1 3/22…Away from FEDspeak”. We believe that sm aller cap life science stocks...
by Raynovich Rod | Mar 12, 2023 | 2020-21 Life Science Portfolios, Macro
Small Cap Biotechs Slammed by SVB Collapse Small Cap biotechs have been hit hard and needs time to sort out. Momentum and sentiment in a risk-off mode. Opportunity to assess good stocks for longer term after seeing how they trade. Nothing like a banking crisis to...
by Raynovich Rod | Mar 6, 2023 | 2020-21 Life Science Portfolios, 2023 Rayno Biopharmaceuticals Portfolio
Update-2 3/9/23… Silicon Valley Bank Collapse triggers more selling in small cap biotechs.Sold XBI at $79 for 4% profit now at $75. Large cap biopharma holding up well in green. Jobs grew solidly but at a slower pace.So looking for a 25 bps rate increase. Risk...
by Raynovich Rod | Feb 26, 2023 | 2020-21 Life Science Portfolios
Update-2 3/2 Better tape action today. Big winners: CRSP, CYRX, NTLA, NVTA, QDEL, PACB,SUPN. Review on Weekend. Cowen conference next week March 8 should help life science sector. Update-1 2/28 Risk Off when FED rules with rates rising. Equities fighting higher...
by Raynovich Rod | Feb 20, 2023 | 2020-21 Life Science Portfolios
SMID Life Science Stocks: Investor or Trader? Despite choppy trading there is an upward tilt to life science stocks since 9/26/22 lows. Three stocks are strong holds: EVH,HOLX and QDEL. Can gene therapy break through in 2023? Our SMID (small and mid) life science...
by Raynovich Rod | Feb 5, 2023 | 2020-21 Life Science Portfolios
Update-2 2/17…QDEL beats on earnings and revenue of $3.37B. EPS of $13.80.Business combination with Ortho still in flux. Stock looks good on technical basis with accumulation. Good value with P/S 1.97, PE is 5.42 and P/FCF 6.45. Recommendation is a...
by Raynovich Rod | Jan 30, 2023 | 2020-21 Life Science Portfolios, 2023 Rayno Biopharmaceuticals Portfolio
Update-4 Mixed stock market in healthcare and biotech but in an overall weak day as FED and CPI looms. IBB down 0.62% to $132 level. Abbvie (ABBV) beats with Revenue of $58.04B an increase of 3.3% but Humira biosimilars weigh on profit forecast ; pipeline and Botox...
